statement
ACR20 reached 92.5%, surpassing 72.7% at week 16 and meeting expectations.
A statement by 하나증권 제약/바이오 김선아. Statements are as reported by the cited publishers — not verified by DecisionGateway.
ACR20 92.5%로 16주차 72.7%를 넘어서며 기대 수치 충족
Discussion
Related claims
The 600mg continuous dosing group recorded an ACR20 value of 92.5%, demonstrating excellent efficacy in absolute terms.report author · statementThe AWACRI index was unchanged at 19.80%.avestagroupuz · statementAWACRI was unchanged at 19.80%, 5.80% above the Central Bank policy rate of 14%, because no bonds were placed or redeemed during the week.avestagroupuz · statementThe AWACRI index of average corporate coupon rates was unchanged at 19.80%.avestagroupuz · statementThe average corporate coupon, measured by AWACRI, was unchanged at 19.80%.Weekly Overview of RSE “Toshkent” · statementACMT2B5 closed at 112.90% of face value, 2.64% above its previous close, with a yield to maturity of 16.28%, 507 bp above government bonds of the same maturity.avestagroupuz · statement